|
⚲
|
| Keyboard |
| Crestline Management LP
✚
|
|
|---|---|
| CRD # | 122711 |
| SEC # | 801-61607 |
| CIK # | 0001536054 |
| AUM | 22.51 B (2026-03-30) |
| Employees | 195 (58% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 817-339-7600 |
| Address | 201 Main Street Fort Worth, TX 76102-3135 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 5 - Fees and Compensation
Each fund client sets forth its specific fee structure (including how it charges fees) in a confidential
explanatory memorandum, similar disclosure document or account agreement provided to (in the case of
an account agreement, executed by) prospective investors in the relevant fund client.
Crestline deducts fees from its fund clients either monthly or quarterly, and either in advance (but not more
than three months in advance) or arrears depending on the individual fund client. Crestline deducts the fees
directly from its fund clients. Crestline generally charges one of, or a combination of, the following:
1. management fees, which are computed on a percentage of assets under management (based on the
net, total asset value before performance-based compensation, capital commitments or capital
contributions depending on the client, as disclosed in the relevant governing documents), that,
depending upon the terms in the governing documents or terms of side letter agreements with
certain investors: (A) are on a sliding scale; (B) are subject to a minimum floor (expressed in dollars
or as a percentage of assets under management); and (C) currently range from 0.10% per annum to
1.75% per annum depending on the fund client (certain fund clients have taken certain actions to
facilitate the sale or liquidation of certain positions in connection with their winding down; such
fund clients do not pay a management fee.); and
2. performance-based allocations, performance-based fees and carried interest compensation, or
performance-based compensation, which are computed on the percentage of capital appreciation
the relevant fund client experiences, which range from 8.75% per annum to 20% per annum and
which, depending upon the terms in the governing documents or terms of side letter agreements
with certain investors, subject to a “hurdle,” “preferred return” and/or a “high watermark.”
“Carried interest compensation” is a term that generally refers to performance-based compensation
to the relevant fund’s general partner or investment manager after repayment of any capital
contributions and an agreed upon preferred return to the investor when investments are realized.
Crestline makes direct investments in securities for certain fund clients (as opposed to investments
in underlying private funds) via special purpose vehicles, for which Crestline may receive
additional performance-based compensation.
In computing net asset values on which to charge fees/allocations, Crestline applies the guidelines in its
written valuation policy. All assets managed by Crestline are valued according to the valuation
methodologies contained in its valuation policies and in accordance with U.S. Generally Accepted
Accounting Principles (GAAP) – Accounting Standards Codification Topic 820, Fair Value Measurement.
Crestline generally does not negotiate its allocations and fees. Under special circumstances, however,
Crestline enters into agreements with certain investors in its fund clients that provide different terms to
those investors. Crestline has the discretion to waive or reduce its management fee and performance-based
compensation for certain of its related persons or service providers invested in its fund clients.
Crestline Management, L.P.
Form ADV Part 2A – Disclosure Brochure
March 30, 2026
Management agreements to which Crestline is a party are terminable based on the provisions outlined in
each of the fund client’s governing documents and in each relevant management agreement. In the event
of termination of an investment advisory contract or management agreement, Crestline will prorate all
unearned, prepaid fees and refund those unearned fees to the fund clients. Investors in those fund clients
are, however, typically not able to withdraw their capital until the end of a quarter and, therefore, do not
receive pro rata refunds. Certain of Crestline’s illiquid fund clients are also subject to termination fees if
terminated without cause as disclosed in the relevant governing documents.
In addition to the fees paid by the fund clients to Crestline Management, L.P. and to Crestline Associates
Holdings, L.P. (via the entities it owns), to the extent the particular strategy involves investing in underlying
private funds or sub-advisors, the underlying funds and sub-advisors will generally also charge expenses,
such as those set forth in the following paragraph, and an asset-based management fee and performance-
based allocation or fee to the fund clients and that is paid by the fund clients, thereby resulting in two layers
of expenses, fees and allocations. Also, non-Crestline fund client investors that directly invest in a separate
managed account investment will also pay fees to the external managers in addition to the fees paid to
Crestline. However, Crestline fund clients that invest in the separate managed account investment program
will not pay two layers of fees to Crestline.
Fund clients will also pay other expenses in addition to the fees paid to Crestline. For example, depending
upon the terms in the governing documents, fund clients pay portfolio transaction costs, brokerage
commissions, transaction fees, custodial and administration fees, audit and legal fees, registration,
licensing, governmental filing fees, costs of background checks of portfolio managers and management of
target investments, lender expenses, transfer taxes, wire transfer fees and other related fees and taxes. For
information regarding expenses for brokerage expenses, see “Brokerage Practices.” In addition, Crestline
has the discretion to use the services of a third party as part of its diligence process (i.e. background checks
and verifications); such diligence services are in addition to the due diligence conducted by Crestline and
... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 7 - Types of Clients
Crestline serves as the investment manager to private domestic fund clients that were formed for the benefit
of U.S. investors, and private offshore fund clients that were formed for the benefit of non-US investors
and U.S. tax-exempt investors. Fund clients include “pooled” investment funds as well as funds for single
investors (including groups of affiliated single investors). Crestline also has a “beta” solutions business
that customizes portfolio overlay and hedging solutions for institutional investors according to the
governing documents of the relevant fund client or investor.
Investors in its fund clients including funds of one (“SMAs”) include:
• governmental plans, state pension and permanent funds, sovereign wealth funds;
• private retirement plans, corporate pensions, multi-employer pensions;
• financial institutions, insurance companies and other institutional clients;
• foundations, endowments and other charitable organizations; and
• family offices and high net worth individuals.
Certain investors invest with Crestline via a managed account held at the investor’s designated custodian
which is then managed by Crestline pursuant to an investment management agreement between Crestline
and the investor.
Crestline provides investment advisory services to one or more clients that are insurance companies.
Additionally, Crestline’s affiliate, CL Re SPC, is a reinsurance company, and another Crestline affiliate,
CLIC, acts as the primary cedant to CL Re SPC.
Crestline also provides investment advisory services to an entity that has elected be regulated as a business
development company under the Investment Company Act of 1940, as amended (the “Investment Company
Act”).
In determining whether to launch a fund client, Crestline will look to whether it will have sufficient capital
to meet its fund client’s investment objectives and return goal. Crestline generally requires investors in its
fund clients to be qualified purchasers, as defined in the Investment Company Act and generally requires a
minimum investment of $1,000,000, although Crestline may accept and has accepted lesser amounts.
Crestline Management, L.P.
Form ADV Part 2A – Disclosure Brochure
March 30, 2026 |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Denali Therapeutics Inc | 0.0 | ||
| SANA Biotechnology Inc | 0.0 | ||
| 8X8 Inc /DE/ | 0.0 | ||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | CL AK Broadstreet LP | 2026-02-27 | 101.4 M | |
| HF | CL Meadow LLC | 2026-02-27 | 24.5 M | |
| HF | Crestline European Capital Solutions Fund II SCSP | [2025-03-31] | 157.7 M | 458.6 M |
| Filed 2025-10-24 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Crestline Portfolio Financing Fund III SCSP | [2025-03-31] | 325.2 M | 424.7 M |
| Filed 2025-11-26 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | CL FLS 1 LP | 2025-02-28 | 3.2 M | |
| HF | CL Green Park LP | [2024-11-27] | 81.4 M | |
| Filed 2024-07-15 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Crestline Lending Solutions LLC | [2024-11-27] | 219.1 M | |
| Filed 2024-08-08 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Crestline Structured Note Issuer I LLC | 2024-08-29 | 291.2 M | |
| Other | Dynamite LP | 2024-08-29 | 10.1 M | |
| HF | CL Nevermore LP | [2024-02-29] | 37.7 M | |
| Filed 2023-11-08 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 1 | 0.5 |
| (f) Pooled investment vehicles | 100 | 12.6 |
| (g) Pension and profit sharing plans | 9 | 4.8 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.8 |
| (j) Other investment advisers | 0 | 0.1 |
| (k) Insurance companies | 5 | 2.6 |
| (l) Sovereign wealth funds and foreign official institutions | 16 | 0.9 |
| (m) Corporations or other businesses not listed above | 0 | 0.1 |
| (n) Other | 0 | 0.0 |
| Total | 135 | 22.5 |
| By Discretionary | ||
| Discretionary | 135 | 22.5 |
| Non-Discretionary | 0 | 0.0 |
| Total | 135 | 22.5 |
| By Non-United States Persons | ||
| Non-United States Persons | 16.2 | |
| United States Persons | 6.3 | |
| Total | 135 | 22.5 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Karla Bodden | Director | 186 | 22 | |
| J Hunter | Director | 61 | 13 | |
| Dennis Hunter | Director | 132 | 12 | |
| Darren Gorman | Director | 124 | 8 | |
| Jane Fleming | Director | 26 | 8 | |
| Robert Watson | Executive Officer | 54 | 5 | |
| Maurice Murphy | Director | 8 | 5 | |
| Therese Collins | Director | 7 | 5 | |
| Crestline Management LP | Executive Officer, Promoter | 87 | 4 | |
| Kevin Ryan | Director | 63 | 4 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001536054] | |
| 13F-NT | [0001536054] | |
| 3 | [0001536054] | |
| 4 | [0001536054] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $6.4B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 5ZQYRF3Z9W001NF39K35 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Midwest Holding Inc MDWT
Voting Common Stock
|
2022-06-14 | Grant | 2,674 | $0.00 | |
|
Midwest Holding Inc MDWT
Voting Common Stock
|
2021-11-11 | Grant | 727 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2021-02-12 | Sell | 2,216,798 | $65.00 | 144,091,870 |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2020-08-12 | Sell | 1,443,247 | $31.65 | 45,678,768 |
|
Midwest Holding Inc MDWT
Stock Option (right to buy) · derivative
|
2020-07-31 | Grant | 50,000 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2020-06-05 | Sell | 1,922,855 | $25.75 | 49,513,516 |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2020-02-26 | Sell | 3,894,764 | $20.25 | 78,868,971 |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2017-12-12 | Conversion | 14,499,999 | ||
|
Denali Therapeutics Inc DNLI
Common Stock
|
2017-12-12 | Conversion | 2,500,000 | ||
|
Denali Therapeutics Inc DNLI
Series A-1 Convertible Preferred Stock · derivative
|
2017-12-12 | Conversion | 14,499,999 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Series A-1 Convertible Preferred Stock · derivative
|
2017-12-12 | Conversion | 743,599 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Series B-1 Convertible Preferred Stock · derivative
|
2017-12-12 | Conversion | 1,875,000 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Series A-2 Convertible Preferred Stock · derivative
|
2017-12-12 | Conversion | 2,500,000 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Series B-1 Convertible Preferred Stock · derivative
|
2017-12-12 | Conversion | 240,000 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Series A-2 Convertible Preferred Stock · derivative
|
2017-12-12 | Conversion | 128,200 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2017-12-12 | Conversion | 240,000 | ||
|
Denali Therapeutics Inc DNLI
Common Stock
|
2017-12-12 | Buy | 275,000 | $18.00 | 4,950,000 |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2017-12-12 | Conversion | 128,200 | ||
|
Denali Therapeutics Inc DNLI
Common Stock
|
2017-12-12 | Conversion | 743,599 | ||
|
Denali Therapeutics Inc DNLI
Common Stock
|
2017-12-12 | Conversion | 1,875,000 | ||
| showing 20 of 33 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Strategic Value Partners LLC
✚
|
CT | 25.61 B |
|
KSL Advisors LLC
✚
|
CO | 25.61 B |
|
Providence Equity Partners LLC
✚
|
RI | 24.12 B |
|
Templeton Asset Management Ltd
✚
|
24.05 B | |
|
New Holland Capital LLC
✚
|
NY | 23.32 B |
|
Benefit Street Partners Limited
✚
|
22.61 B | |
|
Dawson Partners Inc
✚
|
22.14 B | |
|
Lone Pine Capital LLC
✚
|
CT | 21.62 B |
|
OrbiMed Advisors LLC
✚
|
NY | 20.61 B |
|
Hildene Capital Management LLC
✚
|
CT | 20.18 B |